ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements
PDPics / Pixabay

ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements

  Have you ever heard of Orphan Drug designation? This designation, granted by the U.S. Food and Drug Administration (FDA), is given to drugs or biologics that are designed to treat,…

Continue Reading ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements
The NFL’s My Cause My Cleats 2023: Lacing Up for Awareness with Players’ Personal Stories 
Photo by Dave Adamson on Unsplash

The NFL’s My Cause My Cleats 2023: Lacing Up for Awareness with Players’ Personal Stories 

  During the NFL’s My Cause My Cleats initiative, passion and purpose collide on the field. This initiative embodies the profound bond between athletes and the causes that matter to…

Continue Reading The NFL’s My Cause My Cleats 2023: Lacing Up for Awareness with Players’ Personal Stories 
A New Treatment for Diffuse Large B-Cell Lymphoma Could be on its Way to EU Approval
source: shutterstock.com

A New Treatment for Diffuse Large B-Cell Lymphoma Could be on its Way to EU Approval

According to a story from Market Screener, the drug company AbbVie recently announced that its investigational therapy epcoritamab has received a positive opinion from the European Union's Committee for Medicinal…

Continue Reading A New Treatment for Diffuse Large B-Cell Lymphoma Could be on its Way to EU Approval
New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant
source: pixabay.com

New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant

  Omisirge (omidubicel) is the first allogeneic (from a donor) product for SCT that has been the recipient of FDA approval. The FDA's nod moves Omisirge into the realm of…

Continue Reading New Cell Therapy Approved by the FDA to Reduce Risk of Infection After Transplant
Rep. Jamie Raskin Shares Update on DLBCL, Says He is in Remission
https://pixabay.com/en/united-states-capitol-politics-1675539/

Rep. Jamie Raskin Shares Update on DLBCL, Says He is in Remission

In December 2022, Representative Jamie Raskin (D-MD) shared with the public that he had been diagnosed with diffuse large B-cell lymphoma (DLBCL). Although being diagnosed with cancer can be frightening,…

Continue Reading Rep. Jamie Raskin Shares Update on DLBCL, Says He is in Remission
This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma
source: shutterstock.com

This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma

According to a story from BioPharma Dive, the drug company AbbVie has recently announced its decision to withdraw two different approvals for its cancer therapy Imbruvica. The approvals were withdrawn…

Continue Reading This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma
BRUKINSA for MCL Approved in Russia
Source: https://unsplash.com/photos/ZHys6xN7sUE

BRUKINSA for MCL Approved in Russia

BRUKINSA (zanubrutinib), an orally administered Bruton's tyrosine kinase (BTK) inhibitor, has been approved in various countries for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. For…

Continue Reading BRUKINSA for MCL Approved in Russia